PROTHERA
CONFIDENTIAL · INVESTOR REVIEW ONLY
SEED INVESTMENT MEMORANDUM · 2026
A workflow-differentiated bone void filler platform.
ProThera combines next-generation calcium sulfate bone void filler chemistry with a proprietary tray-and-syringe surgical workflow designed to reduce back-table preparation friction in the OR.
Contact ProThera
$400,000 Seed Capital Raise
CAPITAL ASK
$400,000
Funding validation, tray-and-syringe development, manufacturing readiness, and 510(k) pre-submission progress.
12–18 min
current setup drag
< 6 min
projected workflow
WHAT PROTHERA IS
Proven chemistry. Better surgical workflow.
Same Core Chemistry
Absorbable calcium sulfate formulation category with established clinical history across leading predicate bone void fillers.
Exclusive Tray System
Proprietary tray and syringe delivery system designed to streamline preparation and reduce handling steps in the OR.
Surgical-Grade Output
MIS-friendly paste workflow engineered for cleaner, controlled implantation where infection-risk sensitivity matters. Antibiotic-loading potential could support infection treatment or prevention workflows, but must be treated cautiously and would depend on clearance, labeling, and clinical use context.
THE PROBLEM
Bone void filler workflow inefficiency is a measurable OR cost.
BEFORE
12–18 min
Manual mixing and preparation with multiple components, variable consistency, and back-table complexity.
AFTER
< 6 min
Pre-configured tray and syringe workflow with streamlined paste preparation and consistent ready-to-use output.
OR-minute economics
At $30–$100+ per OR minute, setup time becomes measurable economic drag in high-volume procedural environments.
Time ranges reflect internal projections based on workflow modeling, not clinical data.
WHAT $400,000 UNLOCKS
Capital-efficient milestone creation before the next raise.
01
Validation & Testing
Bench testing, biocompatibility, and verification to support the 510(k) submission.
02
Tray + Syringe Development
Final design lock and pilot-scale manufacturing of the proprietary delivery system.
03
Manufacturing Readiness
Qualified contract manufacturer, documented quality system, and pilot production readiness.
04
Regulatory Progress
510(k) pre-submission engagement and submission package preparation.
$400K Capital → FDA Progress → Commercial Proof → Revenue Growth → Strategic Exit
PATHWAY TO REVENUE
An established regulatory path paired with a capital-efficient commercial model.
510(k) Class II pathway
Predicate-based pathway with multiple cleared predicates in the calcium sulfate bone void filler category. Innovation is in workflow and delivery, not novel chemistry; any antibiotic-related infection treatment or prevention use would require careful regulatory positioning and may be off-label depending on final labeling.
IP-protected workflow
Non-provisional patent filed covering the proprietary tray + syringe delivery system and workflow configuration.
~$3–4B global category
ProThera targets the underserved workflow-differentiated segment of an established bone void filler market.
Distributor-led adoption
Orthopedic and spine independent distributor networks support a capital-efficient path versus a direct sales force.
Market figures, revenue projections, and acquisition multiples are illustrative and directional for planning purposes only. No FDA clearance has been obtained; actual outcomes will vary. Antibiotic-related infection treatment or prevention applications are not presented as cleared claims and would require separate regulatory and clinical review.
FOUNDER + OPERATING PLAN
Nicholas Ian Duff
Founder & CEO, ProThera Medical. 10+ years of OR and medical device experience with firsthand visibility into orthopedic bone void filler workflow inefficiency. Leads product development, regulatory strategy, and commercialization planning.
Capital-efficient · Regulatory-aligned · Distributor-led · Built for licensing or strategic acquisition
CLINICAL + MARKET SUPPORT
Surgeon-informed workflow validation
Dr. Daniel Fahim and Dr. Gene Caicco provide clinical advisor support, workflow feedback, and guidance on the path from early clinical evaluation to broader market readiness.
Direct end-user perspective on ProThera’s tray and syringe workflow.
THE ASK & THE END GOAL
$400,000 seed capital to reach a 510(k)-ready platform.
Primary path: license the ProThera delivery platform to an established orthobiologics or spine strategic. Alternate path: strategic acquisition post-clearance and early commercial validation.
INVESTOR CONTACT
nick@prothera.org
Confidential — for investor review only. All projections are illustrative and subject to regulatory, development, commercial, and financing risk.